Cargando…
Ovarian Carcinosarcoma: Effects of Cytoreductive Status and Platinum-Based Chemotherapy on Survival
Objective. To define survival patterns of women with ovarian carcinosarcoma based on patient, tumor, and treatment characteristics. Methods/Materials. A single-institution, retrospective analysis of women diagnosed with ovarian carcinosarcoma from February 1993 to May 2009 was performed. Survival wa...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3678456/ https://www.ncbi.nlm.nih.gov/pubmed/23781249 http://dx.doi.org/10.1155/2013/490508 |
_version_ | 1782272855888625664 |
---|---|
author | Jernigan, Amelia M. Fader, Amanda Nickles Nutter, Benjamin Rose, Peter Tseng, Jill H. Escobar, Pedro F. |
author_facet | Jernigan, Amelia M. Fader, Amanda Nickles Nutter, Benjamin Rose, Peter Tseng, Jill H. Escobar, Pedro F. |
author_sort | Jernigan, Amelia M. |
collection | PubMed |
description | Objective. To define survival patterns of women with ovarian carcinosarcoma based on patient, tumor, and treatment characteristics. Methods/Materials. A single-institution, retrospective analysis of women diagnosed with ovarian carcinosarcoma from February 1993 to May 2009 was performed. Survival was analyzed with Cox proportional hazards ratios and Kaplan Meier tests. Results. Forty-seven cases of primary ovarian carcinosarcoma were identified. Age conveyed an HR 3.28 (95% CI 1.51–7.11, P = 0.003) for death. Compared to Stages I-II, Stage III carried an HR for death of 4.75 (95% CI 1.16–19.4, P = 0.03) and Stage IV disease an HR of 9.13 (95% CI 1.76–47.45, P = 0.009). Compared to those with microscopic residual, women with >1 cm diameter of residual disease after primary cytoreductive surgery had an HR for death of 4.71 (95% CI 1.84–12.09, P = 0.001). At analysis, 59.1% of those who received platinum-based chemotherapy were alive, compared to 23.1% of those who received nonplatinum-based chemotherapy (P = 0.08). Conclusions. Age, stage, and cytoreduction to no gross residual disease are associated with improved survival in women with ovarian carcinosarcoma. Complete surgical cytoreduction should be the goal of surgical management when possible, but the ideal adjuvant treatment regimen remains unclear. |
format | Online Article Text |
id | pubmed-3678456 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-36784562013-06-18 Ovarian Carcinosarcoma: Effects of Cytoreductive Status and Platinum-Based Chemotherapy on Survival Jernigan, Amelia M. Fader, Amanda Nickles Nutter, Benjamin Rose, Peter Tseng, Jill H. Escobar, Pedro F. Obstet Gynecol Int Clinical Study Objective. To define survival patterns of women with ovarian carcinosarcoma based on patient, tumor, and treatment characteristics. Methods/Materials. A single-institution, retrospective analysis of women diagnosed with ovarian carcinosarcoma from February 1993 to May 2009 was performed. Survival was analyzed with Cox proportional hazards ratios and Kaplan Meier tests. Results. Forty-seven cases of primary ovarian carcinosarcoma were identified. Age conveyed an HR 3.28 (95% CI 1.51–7.11, P = 0.003) for death. Compared to Stages I-II, Stage III carried an HR for death of 4.75 (95% CI 1.16–19.4, P = 0.03) and Stage IV disease an HR of 9.13 (95% CI 1.76–47.45, P = 0.009). Compared to those with microscopic residual, women with >1 cm diameter of residual disease after primary cytoreductive surgery had an HR for death of 4.71 (95% CI 1.84–12.09, P = 0.001). At analysis, 59.1% of those who received platinum-based chemotherapy were alive, compared to 23.1% of those who received nonplatinum-based chemotherapy (P = 0.08). Conclusions. Age, stage, and cytoreduction to no gross residual disease are associated with improved survival in women with ovarian carcinosarcoma. Complete surgical cytoreduction should be the goal of surgical management when possible, but the ideal adjuvant treatment regimen remains unclear. Hindawi Publishing Corporation 2013 2013-05-27 /pmc/articles/PMC3678456/ /pubmed/23781249 http://dx.doi.org/10.1155/2013/490508 Text en Copyright © 2013 Amelia M. Jernigan et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Clinical Study Jernigan, Amelia M. Fader, Amanda Nickles Nutter, Benjamin Rose, Peter Tseng, Jill H. Escobar, Pedro F. Ovarian Carcinosarcoma: Effects of Cytoreductive Status and Platinum-Based Chemotherapy on Survival |
title | Ovarian Carcinosarcoma: Effects of Cytoreductive Status and Platinum-Based Chemotherapy on Survival |
title_full | Ovarian Carcinosarcoma: Effects of Cytoreductive Status and Platinum-Based Chemotherapy on Survival |
title_fullStr | Ovarian Carcinosarcoma: Effects of Cytoreductive Status and Platinum-Based Chemotherapy on Survival |
title_full_unstemmed | Ovarian Carcinosarcoma: Effects of Cytoreductive Status and Platinum-Based Chemotherapy on Survival |
title_short | Ovarian Carcinosarcoma: Effects of Cytoreductive Status and Platinum-Based Chemotherapy on Survival |
title_sort | ovarian carcinosarcoma: effects of cytoreductive status and platinum-based chemotherapy on survival |
topic | Clinical Study |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3678456/ https://www.ncbi.nlm.nih.gov/pubmed/23781249 http://dx.doi.org/10.1155/2013/490508 |
work_keys_str_mv | AT jerniganameliam ovariancarcinosarcomaeffectsofcytoreductivestatusandplatinumbasedchemotherapyonsurvival AT faderamandanickles ovariancarcinosarcomaeffectsofcytoreductivestatusandplatinumbasedchemotherapyonsurvival AT nutterbenjamin ovariancarcinosarcomaeffectsofcytoreductivestatusandplatinumbasedchemotherapyonsurvival AT rosepeter ovariancarcinosarcomaeffectsofcytoreductivestatusandplatinumbasedchemotherapyonsurvival AT tsengjillh ovariancarcinosarcomaeffectsofcytoreductivestatusandplatinumbasedchemotherapyonsurvival AT escobarpedrof ovariancarcinosarcomaeffectsofcytoreductivestatusandplatinumbasedchemotherapyonsurvival |